ESTRO 38 Abstract book

S745 ESTRO 38

treatment with radiotherapy or chemotherapy in the past 5 years. Four patients were treated with SBRT after they refused surgery. The mean and median age was 72 years (range 54-89), with a mean follow up of 24 months (see Table1). The 2-year OS and EFS rates were 89.6% and 82.8%, respectively (fig. 1). In the multivariate analysis, significant factors for OS where albumin level HR= 0.05, 95% CI 0.00 - 0.50; p=0.01; and haemoglobin level HR= 0.43, 95% CI 0.22 - 0.83; p=0.01. The 2-year local, regional and distant control rates, were 93.1%, 93.1% and 95.8%, respectively. As expected, T stage was a significant predictive factor for local control (p=0.02). 5 patients died at the end of the follow up, none, however, related to treatment toxicity or tumour progression. In the multivariate analysis, the significant factors for EFS were as well: albumin level HR= 0.10, 95% CI 0.02 - 0.63; p=0.01; and haemoglobin level HR= 0.53, 95% CI 0.32 - 0.85; p=0.01. Multivariate Cox proportional hazards regression was used to determine the optimal cut points: haemoglobin level >12.4g/dL was related with better OS and EFS, HR= 0.06, 95% CI 0.01 - 0.52; p=0.01 and HR= 0.17, 95% CI 0.05 - 0.64; p=0.01 respectively. Moreover, Albumin level >3.7g/dL was related too, with better OS and EFS HR= 0.13, 95% CI 0.02 - 0.78; p=0.03 and HR= 0.04, 95% CI 0.0 - 0.36; p=0.01 respectively.

influenced more by other factors (e.g. cardiac failure) than from lung cancer. Material and Methods We retrospectively reviewed clinical charts and treatment planning of early stage (Stage IA, IB) lung cancer patients treated with SABR between 2008 and 2016. We consider only patients ≥65 years old. All patients underwent at least one FDG-PET/CT exam before SABR. Total dose was 40-52 Gy in 5-8 fractions. The planning target volume was defined as the GTV, identified on CT simulation, plus 5 mm on axial plane and 10 mm on craniocaudal plane. We divided patients into two groups (group A: ≤ 80 years versus group B: > 80 years) and clinical data were compared. LC, PFS and OS were analyzed with log-rank test. Acute and late toxicities were scored with CTCAE v. 4.03. Results A total of 88 patients were treated and analyzed (group A: 55 patients, M/F=38/17, median age= 73 years; group B: 33 patients, M/F=22/11, median age= 83 years). Median follow-up was 26 months (29 for Group A and 23 for Group B). LC at 1, 2 and 3 years was respectively 96%, 91% and 84% in group A vs. 96%, 81% and 81% in group B (p-value= 0.50). PFS at 1, 2 and 3 years was respectively 78%, 65% and 45% in group A vs. 76%, 51% and 39% in group B (p- value=0.59). OS at 1, 2 and 3 years was respectively 85%, 72% and 57% in group A vs. 88%, 58% and 45% in group B (p- value= 0.40). No statistical significance was reached between Group A and B in terms of LC, PFS and OS. No differences in acute toxicity was shown among the two groups. We registered only two cases of late G3 pneumonitis (1 in group A and 1 No significant difference in toxicity and compatible results in LC, PFS and OS were observed between patients younger or older than 80 years and this suggests that SABR is a feasible and effective treatment modality also in elderly population without risks of severe toxicity. EP-1364 Haemoglobin and albumin levels, as clinical predictors in SBRT for early stage NSCLC D.C. Moreno Santiago 1 , A. Giraldo Marin 1 , M. Ramos Albiac 1 , J. Giralt Sagrera 1 1 Vall D´Hebron Hospital, Radiation Oncology, Barcelona, Spain Purpose or Objective The purpose of this study was to investigate serum albumin and haemoglobin levels as prognostics factors of stereotactic body radiotherapy (SBRT) for early stage NSCLC. Numerous authors have reported that sex, age, Eastern Cooperative Oncology Group performance status (PS), tumour size, and T-stage are prognostic factors of early- stage NSCLC treated with SBRT. Following the steps of surgical series, many authors have tried to identify blood examination data commonly available in clinical settings and use that data to predict outcomes of SBRT. Material and Methods Retrospectively, we analyzed pre-treatment levels (considered up to one month prior to treatment) of haemoglobin and albumin to determine the impact on patient outcomes, such as: overall survival (OS); and event-free survival (EFS: local, regional or distance failures; and death), in patients with early stage NSCLC treated with SBRT in our centre, between February 2015 and January 2018. Survival rates were estimated with Kaplan-Meier analysis, and multivariable analysis was completed using Cox proportional hazards model. Results Of all patients with diagnosis of early stage NSCLC treated with SBRT in our centre, 36 were included in this analysis (table 1). None of the patients had received previous in group B). Conclusion

Conclusion In the setting of SBRT for early-stage NSCLC, our results shows that, pre-treatment haemoglobin <12.4g/dL and/or serum albumin <3.7g/dL, are objective laboratory tests, feasible for estimation of prognosis of patients with early stage NSCLC.